The Swiss government ordered 5 million doses of CureVac's mRNA vaccine against Covid-19 in February.
Keystone / Sebastian Gollnow
Swiss pharmaceutical giant Novartis has signed an initial deal to produce the mRNA molecules for the Covid-19 vaccine developed by German biotech firm CureVac.
This content was published on
2 minutes
Keystone-SDA/jdp
Português
pt
Multinacional Novartis vai ajudar a produzir vacina CureVac Covid-19
On Thursday, Novartis said its plant in Kundl, Austria, would start production of the CureVac vaccine (CVnCoV) this summer. It hopes to deliver enough drug substance to produce 50 million doses by the end of the year and plans to accelerate production to reach 200 million doses in 2022. CureVac is also working with German pharmaceutical company Bayer to manufacture its vaccine.
“We are currently expanding our site with additional capacities for the production of mRNA in order to best serve the increasing demand,” said Steffen Lang, Global Head of Novartis Technical Operations, in a press release.
At the end of January, Novartis announced it would also provide manufacturing capacity for Pfizer/BioNTech’s Covid-19 vaccine. Under the deal, Novartis is involved in the fill-and-finish process – taking the bulk mRNA active ingredient from BioNTech and putting it into vials at its facility in Stein, Switzerland.
Novartis says it is considering other agreements to support the global supply of Covid-19 vaccines and therapeutics.
Switzerland has reserved over 30 million vaccine doses from different manufacturers – Pfizer/BioNTech, Moderna, AstraZeneca, Curevac and Novavax – for its population of 8.6 million people. So far, there are two vaccines approved and available in the country, those from Pfizer/BioNTech and Moderna.
The Swiss government secured 5 million doses of the CureVac vaccine in February. It is based on similar mRNA technology as the Pfizer/BioNtech and Moderna vaccines. Swiss firm Lonza is producing the main active vaccine ingredients for the Moderna vaccine for non-US markets at its site in Visp in southern Switzerland.
Popular Stories
More
Swiss Abroad
The citizenship obstacle course facing spouses of Swiss Abroad
This content was published on
The Ethos Foundation recommends that shareholders vote against all compensation-related items at the Annual General Meeting on March 7.
Top Swiss firms close to reaching gender quota in boards
This content was published on
The proportion of women on the boards of directors of the fifty largest listed companies in Switzerland currently stands at 28%.
Swiss committee wants to end government resignations during legislative term
This content was published on
Members of the Federal Council should no longer be able to leave office before the end of their term, according to a House of Representatives committee.
Swiss government seat: Ritter and Pfister nominated to succeed Amherd
This content was published on
Markus Ritter from St Gallen and Martin Pfister from Zug were officially nominated by the Centre Party on Friday to succeed Defence Minister Viola Amherd.
Top Swiss court rejects Russian request for administrative tax assistance
This content was published on
There is currently no reason to transmit banking information to the Russian Federation, the Swiss Federal Court has ruled.
After strike by radiologists, doctors demonstrate in Bern
This content was published on
Following a strike by radiology technicians in Fribourg, doctors, vets, dentists and chiropractors expressed their frustration on Friday outside parliament in the Swiss capital.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
Novartis agrees to help Pfizer-BioNTech produce Covid-19 vaccine
This content was published on
Swiss pharma giant Novartis says it has signed an initial agreement to provide manufacturing capacity for Pfizer and BioNTech's Covid-19 vaccine.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.